Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Completed 3Terminated 2Active not recruiting 2Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Thoracic 1Other solid neoplasm 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 78Melanoma 51Squamous Cell Carcinoma of Head and Neck 40Neoplasm Metastasis 30Neoplasms 27Breast Neoplasms 26Colorectal Neoplasms 23Carcinoma, Renal Cell 23Head and Neck Neoplasms 21Triple Negative Breast Neoplasms 20Carcinoma, Transitional Cell 20Stomach Neoplasms 19Ovarian Neoplasms 17Lung Neoplasms 15Uterine Cervical Neoplasms 12Esophageal Neoplasms 12Carcinoma, Hepatocellular 12Urinary Bladder Neoplasms 11Parkinson Disease 4, Autosomal Dominant Lewy Body 11Pancreatic Neoplasms 10Small Cell Lung Carcinoma 9Multiple Myeloma 9Recurrence 8Endometrial Neoplasms 8Carcinoma, Merkel Cell 8Lymphoma, Non-Hodgkin 7Lymphoma 7Skin Neoplasms 6Mesothelioma 6Hodgkin Disease 6

Interventions

pembrolizumab 2Cisplatin 2Carboplatin 2tocilizumab 1infigratinib 1etoposide phosphate 1avelumab 1apatinib 1antineoplaston AS 2-1 1antineoplaston A10 1Radiotherapy 1Paclitaxel 1Nelfinavir 1Induction Chemotherapy 1Immunohistochemistry 1Ifosfamide 1Fluorouracil 1Fluorescent Antibody Technique 1Flow Cytometry 1Etoposide 1Electroacupuncture 1Dexamethasone 1Biopsy 1Amifostine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Nasopharyngeal Neoplasms × pembrolizumab × Clear all
NCT05070247 2026-01-22

A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

Takeda

Phase 1/2 Terminated
61 enrolled 29 charts
BreastGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Kidney Neoplasms, Liver Neoplasms, Mesothelioma, Nasopharyngeal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

NCT03769467 2024-11-14

Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)

Atara Biotherapeutics

Phase 1/2 Terminated
12 enrolled 8 charts
Head & Neck

Nasopharyngeal Carcinoma, Carcinoma, Head and Neck Neoplasms, Stomatognathic Diseases, Nasopharyngeal Diseases, Nasopharyngeal Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Nose Neoplasms, Otorhinolaryngologic Diseases, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Pharyngeal Neoplasms, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡